Patents by Inventor Ghi Su Kim

Ghi Su Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180209996
    Abstract: Disclosed herein is a marker composition that includes sphingosine 1-phosphate (S1P) lipid and that may be used to predict the risk of fracture or osteoporosis; a kit that includes an antibody that specifically binds to the S1P lipid and that can be used to predict the risk of fracture or osteoporosis; and a method that can be used to obtain information that allows prediction of the risk of fracture or osteoporosis and includes measurements of S1P lipid concentrations by measuring the binding of a S1P-specific antibody to SIP lipid. The S1P lipid disclosed herein is highly expressed in individuals with fracture, regardless of their bone mineral density. Accordingly, it may be useful as a biomarker of the risk of fracture or osteoporosis.
    Type: Application
    Filed: March 21, 2018
    Publication date: July 26, 2018
    Applicant: THE ASAN FOUNDATION
    Inventors: Jung Min KOH, Ghi Su Kim, Seung Hun Lee, Beom Jun Kim
  • Patent number: 9802994
    Abstract: A pharmaceutical composition for preventing or treating a fracture or osteoporosis, includes, as an active ingredient, a gene selected from a group consisting of slit1, slit2, slit3, robo1, robo2 and vilse, or an expressed protein of the gene. A marker composition for predicting the risk of the occurrence of a fracture or osteoporosis includes the protein. A kit for predicting the risk of the occurrence of a fracture or osteoporosis includes an antibody that specifically binds to the protein. An information provision method for predicting the risk of the occurrence of a fracture or osteoporosis includes measuring the level of expression of the slit protein through an antigen-antibody binding reaction using an antibody that specifically binds to the protein. The slit3 may increase bone formation and decrease bone reabsorption in a cellular and animal model, and has a negative correlation with the incidence rate of osteoporosis.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: October 31, 2017
    Assignee: THE ASAN FOUNDATION
    Inventors: Jung-Min Koh, Ghi Su Kim, Seung Hun Lee, Young-Sun Lee, Beom-Jun Kim
  • Publication number: 20150175673
    Abstract: A pharmaceutical composition for preventing or treating a fracture or osteoporosis, includes, as an active ingredient, a gene selected from a group consisting of slit1, slit2, slit3, robo1, robo2 and vilse, or an expressed protein of the gene. A marker composition for predicting the risk of the occurrence of a fracture or osteoporosis includes the protein. A kit for predicting the risk of the occurrence of a fracture or osteoporosis includes an antibody that specifically binds to the protein. An information provision method for predicting the risk of the occurrence of a fracture or osteoporosis includes measuring the level of expression of the slit protein through an antigen-antibody binding reaction using an antibody that specifically binds to the protein. The slit3 may increase bone formation and decrease bone reabsorption in a cellular and animal model, and has a negative correlation with the incidence rate of osteoporosis.
    Type: Application
    Filed: June 14, 2013
    Publication date: June 25, 2015
    Inventors: Jung-Min Koh, Ghi Su Kim, Seung Hun Lee, Young-Sun Lee, Beom-Jun Kim
  • Publication number: 20130331282
    Abstract: Disclosed herein is a marker composition that includes sphingosine 1-phosphate (S1P) protein and that may be used to predict the risk of fracture or osteoporosis; a kit that includes an antibody that specifically binds to the S1P protein and that can be used to predict the risk of fracture or osteoporosis; and a method that can be used to obtain information that allows prediction of the risk of fracture or osteoporosis and includes measurements of S1P protein concentrations by measuring the binding of a S1P-specific antibody to S1P protein. The S1P protein disclosed herein is highly expressed in individuals with fracture, regardless of their bone mineral density. Accordingly, it may be useful as a biomarker of the risk of fracture or osteoporosis.
    Type: Application
    Filed: April 18, 2013
    Publication date: December 12, 2013
    Inventors: Jung Min Koh, Ghi Su Kim, Seung Hun Lee, Beom Jun Kim